Analysts cheer as AbbVie pays $750M cash to ally itself with Genmab on a pipeline of cancer drugs, with billions more on the table
You can count the R&D execs at AbbVie among the believers in Genmab’s bispecific platform tech.
Moving beyond the Allergan buyout, AbbVie refocused on its cancer drug pipeline, shelling out $750 million in cash and promising up to $3.15 billion more in milestones — 60% for development and regulatory goals — to ally itself on a slate of 7 development and discovery programs.
At the front of the queue is the early-stage drug epcoritamab, a CD3xCD20 bispecific from its DuoBody collection. There’s also DuoHexaBody-CD37 and DuoBody-CD3x5T4. And then AbbVie gets to pick and choose from among the discovery work at Genmab for 4 more, with AbbVie adding in its own contributions in the pairing up to come.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.